Ticagrelor is an orally administered, antiplatelet agent that inhibits the prothrombotic effects of ADP on the platelet by antagonizing the P2Y12 receptor. Ticagrelor is a reversibly binding direct-acting P2Y12 antagonist and does not require metabolic activation to achieve its antiplatelet effect. CYP3A4 and CYP3A5 appear to be the enzymes predominantly responsible for the formation of the ticagrelor active and inactive metabolites, AR-C124910XX and AR-C133913XX. The apparent Km values in human liver microsomes are 27.0 and 38.8 μM, with Vmax values of 730 and 417 pmol/min/mg for AR-C124910XX and AR-C133913XX, respectively. Ticagrelor moderately inhibited CYP2C9 activity in human liver microsomes with an IC50 of 10.5 μM, while exhibiting little or no inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C19, CYP2D6, and CYP2E1. In human liver microsomes, ticagrelor inhibited midazolam 4-hydroxylation with an IC50 of 8.2 μM, while activating 1′-hydroxylation of midazolam. Studies with recombinant enzymes suggested that cytochrome b5 and CYP3A4 interactions play a significant role in this differential kinetic behavior. Evaluated in fresh human hepatocytes at concentration up to 20 μM, ticagrelor was not an inducer of CYP1A2 or CYP3A4. Although ticagrelor exhibited a tendency for CYP2B6 and CYP2C9 induction, its potential to cause drug interactions via the induction of these enzymes is low when its exposure at a therapeutic dose is considered.
Footnotes
This work was supported by AstraZeneca.
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.110.037143.
-
ABBREVIATIONS:
- P450
- cytochrome P450
- HLM
- human liver microsomes
- Cyt b5
- cytochrome b5
- BNF
- β-naphthoflavone
- PB
- phenobarbital
- RIF
- rifampin
- AUC
- area under the curve
- CT
- threshold cycle.
- Received November 10, 2010.
- Accepted December 22, 2010.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|